Identifying the Anti-Blood-Clotting Compounds in Garlic

Status Completed

Clinical Trial Summary

This study will seek to identify the compound(s) in garlic that is (are) responsible for its ability to prevent the formation of blood clots (prevent platelet aggregation) and to determine the maximally effective dose and duration of the benefits. This study will also determine whether "cooked" garlic (garlic powder added to boiling water, no allicin present) is as effective as "fresh" garlic (garlic powder added to ambient water, high allicin present) and, if more than one compound is involved, and whether their combined effects are more significant than the effects of each compound alone.

Clinical Trial Description

Published studies indicate that various types of undefined garlic products display antiplatelet activity. However, the compounds responsible for this antiplatelet effect have not been identified.

Acute studies. In acute (one day) studies, healthy participants will consume several doses of "fresh garlic" (garlic powder added to ambient water; up to the equivalent of 12 grams fresh garlic or 52 mg allicin) as a paste in a tuna sandwich. At 0, 2, 4, and 6 hours after consumption, the ability of platelets to aggregate in platelet-rich plasma (PRP) or in whole blood (WB), in response to a drug (collagen, ADP) that stimulates platelet aggregation, will be measured. After establishing the optimum dose and optimum time of the antiplatelet effect for each person, and if the effects are sufficiently strong, the effects of cooked garlic (garlic powder added to boiling water, no allicin present) and seven extracted fractions (oil, protein, fructans, etc.) will be determined, using the fractions at the same dose as their abundance in the established optimum dose of crushed fresh garlic.

Chronic studies. If only weak platelet effects are found for a high acute dose of "fresh" garlic, chronic studies will be conducted. In chronic studies, participants will consume 8.0 grams of "fresh garlic" (2.7 grams garlic powder added to ambient water, allicin content = 35 mg) as a paste in a tuna sandwich every day for four weeks and 8.0 grams of "boiled garlic" (2.7 grams garlic powder added to boiling water) in a sandwich every day for an additional four weeks, after a 1-week washout. The ability of platelets to aggregate in PRP and whole blood will be determined before and every week after garlic consumption begins and after the 1-week washout. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00200785
Study type	Interventional
Source	National Center for Complementary and Integrative Health (NCCIH)
Contact
Status	Completed
Phase	N/A
Start date	March 2006
Completion date	September 2007

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06032572` - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)	N/A
Not yet recruiting	`NCT02866656` - The Clinical Research of Low Intensity Continuous Ultrasonic on Lower Limb Arteriosclerosis Occlusion（ASO） Syndrome	N/A
Completed	`NCT02510547` - Comparison of a CrossBoss First Versus Standard Wire Escalation Strategy for Crossing Coronary Chronic Total Occlusion: the "CrossBoss First" Trial	Phase 4
Completed	`NCT02264717` - Dan-NICAD - Danish Study of Non-Invasive Diagnostic Testing in Coronary Artery Disease	N/A
Completed	`NCT01334268` - RESOLUTE China RCT	N/A
Active, not recruiting	`NCT00154180` - Kronos Early Estrogen Prevention Study (KEEPS)	Phase 4
Recruiting	`NCT04343209` - Ammonia N-13 Myocardial Blood Flow Absolute Quantification by PET in Patients With Known or Suspected CAD (Ammonia MAP)
Not yet recruiting	`NCT06039748` - Angiography-Derived Quantitative Functional Assessment Versus Pressure-Derived FFR and IMR: The FAIR Study
Recruiting	`NCT04142021` - Safety and Feasibility Evaluation of Planning and Execution of Surgical Revascularization Solely Based on Coronary CTA and FFRCT in Patients With Complex Coronary Artery Disease (FASTTRACK CABG)
Recruiting	`NCT06008756` - MK-0616 (Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes	Phase 3
Completed	`NCT03253692` - Prospective Multicenter Registry On Radiation Dose Estimates Of Cardiac CT Angiography in Daily Practice in 2017 (PROTECTION VI)
Active, not recruiting	`NCT04624854` - Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD)	Phase 4
Active, not recruiting	`NCT02921230` - Trial Comparing ELUVIA Versus Bare Metal Stent in Treatment of Superficial Femoral and/or Proximal Popliteal Artery	N/A
Recruiting	`NCT01774058` - The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation	Phase 2
Terminated	`NCT01462721` - The eSVS® Mesh Randomized Post-Market Study	N/A
Completed	`NCT01221610` - BIOLUX P-I First in Man Study	N/A
Completed	`NCT01455974` - The Effects of Lowering Dialysate Sodium in Hypertensive Hemodialysis Patients	N/A
Active, not recruiting	`NCT00174902` - The Effect of Beta-Blockers and Aspirin on Hemostasis and Endothelial Function After Acute Mental Stress	Phase 1/Phase 2
Active, not recruiting	`NCT00863967` - Early Detection of Arteriosclerosis	N/A
Completed	`NCT00050817` - Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)	Phase 3